Judy Dering

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro

Richard S. Finn, Judy Dering, Dylan Conklin et al. · Breast Cancer Research · 2009 · 1.4K citations · Full text

Medicine, Oncology, Pharmacology +17

Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast Cancer

Angelo Di Leo, Henry Gómez, Zeba Aziz et al. · Journal of Clinical Oncology · 2008 · 421 citations · Full text

Medicine, Oncology, Pharmacology +17

Prognostic and Therapeutic Relevance of Molecular Subtypes in High-Grade Serous Ovarian Cancer

Gottfried E. Konecny, Chen Wang, Habib Hamidi et al. · JNCI Journal of the National Cancer Institute · 2014 · 408 citations · Full text

Medicine, Cancer Biology, Oncology +17

A Collagen-Remodeling Gene Signature Regulated by TGF-β Signaling Is Associated with Metastasis and Poor Survival in Serous Ovarian Cancer

Dong‐Joo Cheon, Yunguang Tong, Myung‐Shin Sim et al. · Clinical Cancer Research · 2013 · 407 citations · Full text

Medicine, Cancer Biology, Oncology +17

Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/“triple-negative” breast cancer cell lines growing in vitro

Richard S. Finn, Judy Dering, Charles Ginther et al. · Breast Cancer Research and Treatment · 2007 · 403 citations · Full text

Medicine, Molecular Biology, Pharmacology +17